Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Genticel announces its financial communication calendar for 2015



GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today announces its financial communication agenda for 2015. This calendar of publication dates is for reference only; it is subject to change if necessary. Each publication will be released after Euronext market closing.
































27 January 2015 Business & Cash Position Update 4th Quarter 2014
2 March 2015 2014 Annual Results
28 April 2015 Business & Cash Position Update 1st Quarter 2015
11 June 2015 Annual Shareholders Meeting
28 July 2015 Business & Cash Position Update 2nd Quarter 2015
21 September 2015 2015 Half-Year Results
28 October 2015 Business & Cash Position Update 3rd Quarter 2015

About Genticel

Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.


Genticel's most advanced candidate therapeutic vaccine, ProCervix, is currently in a Phase II clinical trial. ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18.


Genticel is based in Paris and Toulouse and was awarded the Deloitte Technology Fast 50 “Prix Biotech d'Avenir” (Most promising Biotech) in 2014.


Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels. For more information, please visit www.genticel.com




CONTACT GENTICEL

Benedikt Timmerman

Chief Executive Officer

[email protected]

 


USA INVESTOR CONTACT

Brian Stollar


Tel.: +1 (212) 915 2577

[email protected]

 


INVESTOR CONTACT

Corinne Puissant

Tel.: +33 (0)1 53 67 36 77

[email protected]

 


PRESS CONTACT

Alexandra Prisa

Tel.: +33 (0)1 53 67 36 90

[email protected]


Information réglementée
Communiqués au titre de l'obligation d'information permanente :

- Autres communiqués

Communiqué intégral et original au format PDF :


http://www.actusnews.com/documents_communiques/ACTUS-0-38572-150121_GENTICEL-Financial-Calendar_-UK-2.pdf

© Copyright Actusnews Wire

Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com

Receive by email the next press releases of the company by registering on www.actusnews.com, it's free



Quelle: Actusnews

GenKyoTex S.A. Aktie

3,18 €
0,16 %
Leichte Gewinne bei GenKyoTex S.A. heute, der Kurs steigt um 0,16 %.

Like: 0
Teilen

Kommentare